Bladder Cancer Clinical Trial

Intravesical BCG vs GEMDOCE in NMIBC

Summary

The study hypothesis is that BCG naïve non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will result in a non-inferior event-free survival (EFS) compared to standard treatment with intravesical BCG. The purpose of this study is to test whether Gemcitabine + Docetaxel is a better or worse treatment than the usual BCG therapy approach. The primary objective of this study is to determine the event free survival (EFS) of BCG-naïve high grade non-muscle invasive bladder cancer patients treated with intravesical BCG vs Gemcitabine + Docetaxel. Secondary objectives are as follows: to compare changes in cancer-specific and bladder cancer-specific QOL from baseline to treatment between BCG-naïve high grade NMIBC patients receiving BCG and GEMDOCE, to determine the cystectomy free survival (CFS) of BCG-naïve high grade NMIBC patients treated with intravesical BCG vs GEMDOCE, to determine the progression free survival (PFS) of BCG-naïve high grade NMIBC patients treated with intravesical BCG vs GEMDOCE, and to determine the safety and toxicity of BCG-naïve high grade NMIBC patients treated with intravesical BCG vs GEMDOCE.

View Full Description

Full Description

The primary objective of this study is to determine the event free survival (EFS) of BCG-naïve high grade non-muscle invasive bladder cancer patients treated with intravesical BCG vs Gemcitabine + Docetaxel. Secondary objectives are as follows: to compare changes in cancer-specific and bladder cancer-specific QOL from baseline to treatment between BCG-naïve high grade NMIBC patients receiving BCG and GEMDOCE, to determine the cystectomy free survival (CFS) of BCG-naïve high grade NMIBC patients treated with intravesical BCG vs GEMDOCE, to determine the progression free survival (PFS) of BCG-naïve high grade NMIBC patients treated with intravesical BCG vs GEMDOCE, and to determine the safety and toxicity of BCG-naïve high grade NMIBC patients treated with intravesical BCG vs GEMDOCE

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patient must be > 18 years of age.
Patient must have histologically confirmed high-grade non-muscle invasive urothelial carcinoma of the bladder (HgTa, HGT1, CIS, HgTa + CIS, or HGT1 + CIS stage) on transurethral resection of bladder tumor (TURBT) obtained within 90 days prior to randomization.
Patient must have all visible papillary tumor resected by the treating urologist at the site registering the patient to this protocol prior to randomization. If the treating urologist did not perform the TURBT as outlined in Section 3.1.3, the treating urologist must perform a cystoscopy within 28 days prior to randomization to confirm the absence of visible papillary disease.
Patient must have not received prior intravesical therapy for bladder cancer, with the exception of perioperative chemotherapy at the time of TURBT.
Patients with high grade T1 disease must have undergone a restaging TURBT within 90 days prior to Step 1 randomization.

NOTE: Patients with high grade T1 disease who undergo a restaging TURBT that shows no residual cancer in the restaging TURBT specimen are eligible.

Patient must not have pure squamous cell carcinoma or adenocarcinoma.
Patient must not have any component of neuroendocrine carcinoma (i.e., small cell or large cell).
Patient must not have any component of sarcomatoid, micropapillary, or plasmacytoid variant histology.
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
Patient must have ECOG Performance Status 0-2.
Patient may have received prior systemic gemcitabine or docetaxel use if it was for a non-bladder malignancy.
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible.
Patient must have adequate organ and marrow function as defined below (these labs must be obtained ≤ 28 days prior to randomization):

Leukocytes ≥ 3,000/mcL Leukocytes:__________ Date of Test:__________ Absolute neutrophil count (ANC) ≥ 1,500/mcL ANC:__________ Date of Test:__________ Platelets ≥ 70,000/mcL Platelets:__________ Date of Test:__________ Total Bilirubin ≤ institutional upper limit of normal (ULN) Total Bilirubin:__________ Institutional ULN:_________ Date of Test:__________ AST(SGOT)/ALT(SGPT) ≤ 3.0 × institutional ULN AST:_______ Institutional ULN:_________ Date of Test:_______ ALT: _______Institutional ULN:_________

Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial.
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.

Exclusion Criteria:

Patient must not have any prior or current history of muscle-invasive (i.e., T2, T3, T4), locally advanced unresectable, or metastatic urothelial carcinoma as assessed on radiographic imaging obtained within 90 days prior to randomization. The radiographic imaging includes a CT Scan OR MRI of the abdomen/pelvis with intravenous contrast.

NOTE: If a patient's renal function does not permit the administration of intravenous contrast, either a CT scan or MRI of the abdomen/pelvis without intravenous contrast is acceptable.

NOTE: Patients with a history of non-invasive (Ta, Tis) upper tract urothelial carcinoma that has been definitively treated with at least one post-treatment disease assessment (i.e., either cytology, biopsy, or imaging) that demonstrates no evidence of residual disease are eligible.

- Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used.

All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy.

A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).

Patient of child bearing potential? ______ (Yes or No) Date of blood test or urine study: ___________

Patient must not expect to conceive or father children by using an accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study. In addition,patients on Arm A must continue contraception measures for six months after the last dose of GEMDOCE for patients of child-bearing potential and continue for three month after the last dose of GEMDOC for male patients with partners of child-bearing potential. All patients must not breastfeed during their time on protocol treatment.
Patient must not have a history of severe hypersensitivity reactions to docetaxel or drugs formulated with polysorbate 80.

Study is for people with:

Bladder Cancer

Phase:

Phase 3

Estimated Enrollment:

870

Study ID:

NCT05538663

Recruitment Status:

Recruiting

Sponsor:

ECOG-ACRIN Cancer Research Group

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 103 Locations for this study

See Locations Near You

University of Alabama at Birmingham Cancer Center
Birmingham Alabama, 35233, United States More Info
Site Public Contact
Contact
205-934-0220
[email protected]
Charles C. Peyton
Principal Investigator
Fairbanks Memorial Hospital
Fairbanks Alaska, 99701, United States More Info
Site Public Contact
Contact
907-458-3043
[email protected]
Nicholas DiBella
Principal Investigator
Banner MD Anderson Cancer Center
Gilbert Arizona, 85234, United States More Info
Site Public Contact
Contact
602-747-9738
Chinedu Mmeje
Principal Investigator
Mercy Hospital Fort Smith
Fort Smith Arkansas, 72903, United States More Info
Site Public Contact
Contact
800-378-9373
Jay W. Carlson
Principal Investigator
Rocky Mountain Cancer Centers-Aurora
Aurora Colorado, 80012, United States More Info
Site Public Contact
Contact
303-777-2663
[email protected]
Nicholas DiBella
Principal Investigator
University of Colorado Hospital
Aurora Colorado, 80045, United States More Info
Site Public Contact
Contact
720-848-0650
Janet E. Kukreja
Principal Investigator
Boulder Community Foothills Hospital
Boulder Colorado, 80303, United States More Info
Site Public Contact
Contact
303-777-2663
[email protected]
Nicholas DiBella
Principal Investigator
Rocky Mountain Cancer Centers-Boulder
Boulder Colorado, 80304, United States More Info
Site Public Contact
Contact
303-777-2663
[email protected]
Nicholas DiBella
Principal Investigator
Rocky Mountain Cancer Centers - Centennial
Centennial Colorado, 80112, United States More Info
Site Public Contact
Contact
303-777-2663
[email protected]
Nicholas DiBella
Principal Investigator
The Women's Imaging Center
Denver Colorado, 80209, United States More Info
Site Public Contact
Contact
303-777-2663
[email protected]
Nicholas DiBella
Principal Investigator
Colorado Blood Cancer Institute
Denver Colorado, 80218, United States More Info
Site Public Contact
Contact
303-777-2663
[email protected]
Nicholas DiBella
Principal Investigator
Presbyterian - Saint Lukes Medical Center - Health One
Denver Colorado, 80218, United States More Info
Site Public Contact
Contact
303-777-2663
[email protected]
Nicholas DiBella
Principal Investigator
Rocky Mountain Cancer Centers-Midtown
Denver Colorado, 80218, United States More Info
Site Public Contact
Contact
303-777-2663
[email protected]
Nicholas DiBella
Principal Investigator
Rocky Mountain Cancer Centers-Rose
Denver Colorado, 80220, United States More Info
Site Public Contact
Contact
303-777-2663
[email protected]
Nicholas DiBella
Principal Investigator
Rose Medical Center
Denver Colorado, 80220, United States More Info
Site Public Contact
Contact
303-777-2663
[email protected]
Nicholas DiBella
Principal Investigator
Mountain Blue Cancer Care Center - Swedish
Englewood Colorado, 80113, United States More Info
Site Public Contact
Contact
303-777-2663
[email protected]
Nicholas DiBella
Principal Investigator
Rocky Mountain Cancer Centers - Swedish
Englewood Colorado, 80113, United States More Info
Site Public Contact
Contact
303-777-2663
[email protected]
Nicholas DiBella
Principal Investigator
Swedish Medical Center
Englewood Colorado, 80113, United States More Info
Site Public Contact
Contact
303-777-2663
[email protected]
Nicholas DiBella
Principal Investigator
The Melanoma and Skin Cancer Institute
Englewood Colorado, 80113, United States More Info
Site Public Contact
Contact
[email protected]
Nicholas DiBella
Principal Investigator
Rocky Mountain Cancer Centers-Lakewood
Lakewood Colorado, 80228, United States More Info
Site Public Contact
Contact
303-777-2663
[email protected]
Nicholas DiBella
Principal Investigator
Rocky Mountain Cancer Centers-Littleton
Littleton Colorado, 80120, United States More Info
Site Public Contact
Contact
303-777-2663
[email protected]
Nicholas DiBella
Principal Investigator
Rocky Mountain Cancer Centers-Sky Ridge
Lone Tree Colorado, 80124, United States More Info
Site Public Contact
Contact
303-777-2663
[email protected]
Nicholas DiBella
Principal Investigator
Rocky Mountain Cancer Centers-Thornton
Thornton Colorado, 80260, United States More Info
Site Public Contact
Contact
303-777-2663
[email protected]
Nicholas DiBella
Principal Investigator
MedStar Georgetown University Hospital
Washington District of Columbia, 20007, United States More Info
Site Public Contact
Contact
202-444-2223
Lambros Stamatakis
Principal Investigator
MedStar Washington Hospital Center
Washington District of Columbia, 20010, United States More Info
Site Public Contact
Contact
202-877-8839
Lambros Stamatakis
Principal Investigator
Sibley Memorial Hospital
Washington District of Columbia, 20016, United States More Info
Site Public Contact
Contact
202-243-2373
[email protected]
Sunil H. Patel
Principal Investigator
George Washington University Medical Center
Washington District of Columbia, 20037, United States More Info
Site Public Contact
Contact
202-741-2981
Michael J. Whalen
Principal Investigator
University of Florida Health Science Center - Gainesville
Gainesville Florida, 32610, United States More Info
Site Public Contact
Contact
352-273-8010
[email protected]
Padraic O'Malley
Principal Investigator
Saint Anthony's Health
Alton Illinois, 62002, United States More Info
Site Public Contact
Contact
618-463-5623
Jay W. Carlson
Principal Investigator
Saint Mary's Hospital
Centralia Illinois, 62801, United States More Info
Site Public Contact
Contact
[email protected]
Jay W. Carlson
Principal Investigator
NorthShore University HealthSystem-Evanston Hospital
Evanston Illinois, 60201, United States More Info
Site Public Contact
Contact
847-570-2109
Nicklas R. Pfanzelter
Principal Investigator
NorthShore University HealthSystem-Glenbrook Hospital
Glenview Illinois, 60026, United States More Info
Site Public Contact
Contact
847-570-2109
Nicklas R. Pfanzelter
Principal Investigator
NorthShore University HealthSystem-Highland Park Hospital
Highland Park Illinois, 60035, United States More Info
Site Public Contact
Contact
847-570-2109
Nicklas R. Pfanzelter
Principal Investigator
Good Samaritan Regional Health Center
Mount Vernon Illinois, 62864, United States More Info
Site Public Contact
Contact
618-242-4600
Jay W. Carlson
Principal Investigator
North Shore Medical Center
Skokie Illinois, 60076, United States More Info
Site Public Contact
Contact
[email protected]
Nicklas R. Pfanzelter
Principal Investigator
Reid Health
Richmond Indiana, 47374, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Mary Greeley Medical Center
Ames Iowa, 50010, United States
McFarland Clinic PC - Ames
Ames Iowa, 50010, United States
McFarland Clinic PC-Boone
Boone Iowa, 50036, United States
McFarland Clinic PC-Trinity Cancer Center
Fort Dodge Iowa, 50501, United States
McFarland Clinic PC-Jefferson
Jefferson Iowa, 50129, United States
McFarland Clinic PC-Marshalltown
Marshalltown Iowa, 50158, United States
Central Care Cancer Center - Garden City
Garden City Kansas, 67846, United States More Info
Site Public Contact
Contact
913-948-5588
[email protected]
Jay W. Carlson
Principal Investigator
Central Care Cancer Center - Great Bend
Great Bend Kansas, 67530, United States More Info
Site Public Contact
Contact
913-948-5588
[email protected]
Jay W. Carlson
Principal Investigator
University of Kentucky/Markey Cancer Center
Lexington Kentucky, 40536, United States More Info
Site Public Contact
Contact
859-257-3379
Patrick J. Hensley
Principal Investigator
Mercy Health - Paducah Medical Oncology and Hematology
Paducah Kentucky, 42003, United States More Info
Site Public Contact
Contact
270-538-5632
[email protected]
Nicholas DiBella
Principal Investigator
LSU Healthcare Network / Metairie Multi-Specialty Clinic
Metairie Louisiana, 70006, United States More Info
Site Public Contact
Contact
504-210-3539
[email protected]
Mary E. Westerman
Principal Investigator
Louisiana State University Health Science Center
New Orleans Louisiana, 70112, United States More Info
Site Public Contact
Contact
504-210-3539
[email protected]
Mary E. Westerman
Principal Investigator
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore Maryland, 21287, United States More Info
Site Public Contact
Contact
410-955-8804
[email protected]
Sunil H. Patel
Principal Investigator
Brigham and Women's Hospital
Boston Massachusetts, 02115, United States More Info
Site Public Contact
Contact
617-724-5200
Mark A. Preston
Principal Investigator
University of Michigan Comprehensive Cancer Center
Ann Arbor Michigan, 48109, United States More Info
Site Public Contact
Contact
800-865-1125
Todd M. Morgan
Principal Investigator
Saint Louis Cancer and Breast Institute-Ballwin
Ballwin Missouri, 63011, United States More Info
Site Public Contact
Contact
314-251-7058
Jay W. Carlson
Principal Investigator
Central Care Cancer Center - Bolivar
Bolivar Missouri, 65613, United States More Info
Site Public Contact
Contact
913-948-5588
[email protected]
Jay W. Carlson
Principal Investigator
Cox Cancer Center Branson
Branson Missouri, 65616, United States More Info
Site Public Contact
Contact
417-269-4520
Jay W. Carlson
Principal Investigator
Freeman Health System
Joplin Missouri, 64804, United States More Info
Site Public Contact
Contact
417-347-4030
[email protected]
Jay W. Carlson
Principal Investigator
Mercy Hospital Joplin
Joplin Missouri, 64804, United States More Info
Site Public Contact
Contact
417-556-3074
[email protected]
Jay W. Carlson
Principal Investigator
Delbert Day Cancer Institute at PCRMC
Rolla Missouri, 65401, United States More Info
Site Public Contact
Contact
573-458-7504
[email protected]
Jay W. Carlson
Principal Investigator
Mercy Clinic-Rolla-Cancer and Hematology
Rolla Missouri, 65401, United States More Info
Site Public Contact
Contact
573-458-6379
Jay W. Carlson
Principal Investigator
Heartland Regional Medical Center
Saint Joseph Missouri, 64506, United States More Info
Site Public Contact
Contact
816-271-7937
[email protected]
Jay W. Carlson
Principal Investigator
Saint Louis Cancer and Breast Institute-South City
Saint Louis Missouri, 63109, United States More Info
Site Public Contact
Contact
314-353-1870
Jay W. Carlson
Principal Investigator
Mercy Hospital South
Saint Louis Missouri, 63128, United States More Info
Site Public Contact
Contact
[email protected]
Jay W. Carlson
Principal Investigator
Mercy Hospital Saint Louis
Saint Louis Missouri, 63141, United States More Info
Site Public Contact
Contact
314-251-7066
Jay W. Carlson
Principal Investigator
Mercy Hospital Springfield
Springfield Missouri, 65804, United States More Info
Site Public Contact
Contact
417-269-4520
Jay W. Carlson
Principal Investigator
CoxHealth South Hospital
Springfield Missouri, 65807, United States More Info
Site Public Contact
Contact
417-269-4520
Jay W. Carlson
Principal Investigator
Mercy Hospital Washington
Washington Missouri, 63090, United States More Info
Site Public Contact
Contact
636-390-1600
Jay W. Carlson
Principal Investigator
Memorial Sloan Kettering Basking Ridge
Basking Ridge New Jersey, 07920, United States More Info
Site Public Contact
Contact
212-639-7592
Eugene J. Pietzak
Principal Investigator
Hackensack University Medical Center
Hackensack New Jersey, 07601, United States More Info
Site Public Contact
Contact
201-996-2879
Nitin Yerram
Principal Investigator
Memorial Sloan Kettering Monmouth
Middletown New Jersey, 07748, United States More Info
Site Public Contact
Contact
212-639-7592
Eugene J. Pietzak
Principal Investigator
Memorial Sloan Kettering Bergen
Montvale New Jersey, 07645, United States More Info
Site Public Contact
Contact
212-639-7592
Eugene J. Pietzak
Principal Investigator
University of New Mexico Cancer Center
Albuquerque New Mexico, 87102, United States More Info
Site Public Contact
Contact
505-925-0348
[email protected]
Frances M. Alba
Principal Investigator
Albany Medical Center
Albany New York, 12208, United States More Info
Site Public Contact
Contact
518-262-5513
Badar M. Mian
Principal Investigator
Roswell Park Cancer Institute
Buffalo New York, 14263, United States More Info
Site Public Contact
Contact
800-767-9355
[email protected]
Qiang J. Li
Principal Investigator
Memorial Sloan Kettering Commack
Commack New York, 11725, United States More Info
Site Public Contact
Contact
212-639-7592
Eugene J. Pietzak
Principal Investigator
Memorial Sloan Kettering Westchester
Harrison New York, 10604, United States More Info
Site Public Contact
Contact
212-639-7592
Eugene J. Pietzak
Principal Investigator
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States More Info
Site Public Contact
Contact
212-639-7592
Eugene J. Pietzak
Principal Investigator
Stony Brook University Medical Center
Stony Brook New York, 11794, United States More Info
Site Public Contact
Contact
800-862-2215
Massimiliano Spaliviero
Principal Investigator
Memorial Sloan Kettering Nassau
Uniondale New York, 11553, United States More Info
Site Public Contact
Contact
212-639-7592
Eugene J. Pietzak
Principal Investigator
Indu and Raj Soin Medical Center
Beavercreek Ohio, 45431, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Saint Elizabeth Boardman Hospital
Boardman Ohio, 44512, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Dayton Physicians LLC-Miami Valley South
Centerville Ohio, 45459, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Oncology Hematology Care Inc-Kenwood
Cincinnati Ohio, 45236, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Ohio State University Comprehensive Cancer Center
Columbus Ohio, 43210, United States More Info
Site Public Contact
Contact
800-293-5066
[email protected]
Kamal S. Pohar
Principal Investigator
Dayton Physician LLC-Miami Valley Hospital North
Dayton Ohio, 45415, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Armes Family Cancer Center
Findlay Ohio, 45840, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Blanchard Valley Hospital
Findlay Ohio, 45840, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Orion Cancer Care
Findlay Ohio, 45840, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Dayton Physicians LLC-Atrium
Franklin Ohio, 45005, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Dayton Physicians LLC-Wayne
Greenville Ohio, 45331, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Wayne Hospital
Greenville Ohio, 45331, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Greater Dayton Cancer Center
Kettering Ohio, 45409, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Kettering Medical Center
Kettering Ohio, 45429, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Dayton Physicians LLC - Troy
Troy Ohio, 45373, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Saint Joseph Warren Hospital
Warren Ohio, 44484, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Saint Elizabeth Youngstown Hospital
Youngstown Ohio, 44501, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
University of Oklahoma Health Sciences Center
Oklahoma City Oklahoma, 73104, United States More Info
Site Public Contact
Contact
405-271-8777
[email protected]
Sanjay G. Patel
Principal Investigator
Mercy Hospital Oklahoma City
Oklahoma City Oklahoma, 73120, United States More Info
Site Public Contact
Contact
405-752-3402
Jay W. Carlson
Principal Investigator
Oregon Health and Science University
Portland Oregon, 97239, United States More Info
Site Public Contact
Contact
503-494-1080
[email protected]
Jen-Jane Liu
Principal Investigator
Penn State Milton S Hershey Medical Center
Hershey Pennsylvania, 17033, United States More Info
Site Public Contact
Contact
717-531-3779
[email protected]
Matthew G. Kaag
Principal Investigator
Fox Chase Cancer Center
Philadelphia Pennsylvania, 19111, United States More Info
Site Public Contact
Contact
215-728-4790
Andres F. Correa
Principal Investigator
Fox Chase Cancer Center-Rockledge
Rockledge Pennsylvania, 19046, United States More Info
Site Public Contact
Contact
[email protected]
Andres F. Correa
Principal Investigator
AnMed Health Cancer Center
Anderson South Carolina, 29621, United States More Info
Site Public Contact
Contact
864-512-4651
[email protected]
John E. Doster
Principal Investigator
Ralph H Johnson VA Medical Center
Charleston South Carolina, 29401, United States More Info
Site Public Contact
Contact
843-789-7020
[email protected]
Stephen J. Savage
Principal Investigator
Medical University of South Carolina
Charleston South Carolina, 29425, United States More Info
Site Public Contact
Contact
843-792-9321
[email protected]
Stephen J. Savage
Principal Investigator
Prisma Health Greenville Memorial Hospital
Greenville South Carolina, 29605, United States More Info
Site Public Contact
Contact
864-241-6251
Ryan Werntz
Principal Investigator
Lexington Medical Center
West Columbia South Carolina, 29169, United States
University of Texas Medical Branch
Galveston Texas, 77555, United States More Info
Site Public Contact
Contact
409-772-1950
[email protected]
Stephen B. Williams
Principal Investigator
M D Anderson Cancer Center
Houston Texas, 77030, United States More Info
Site Public Contact
Contact
877-632-6789
[email protected]
Kelly Bree
Principal Investigator
UTMB Cancer Center at Victory Lakes
League City Texas, 77573, United States More Info
Site Public Contact
Contact
800-917-8906
Stephen B. Williams
Principal Investigator
Jefferson Healthcare
Port Townsend Washington, 98368, United States More Info
Site Public Contact
Contact
360-344-3091
Nicholas DiBella
Principal Investigator
FHCC South Lake Union
Seattle Washington, 98109, United States More Info
Site Public Contact
Contact
800-804-8824
Jonathan L. Wright
Principal Investigator
Fred Hutchinson Cancer Research Center
Seattle Washington, 98109, United States More Info
Site Public Contact
Contact
800-804-8824
Jonathan L. Wright
Principal Investigator
University of Washington Medical Center - Montlake
Seattle Washington, 98195, United States More Info
Site Public Contact
Contact
800-804-8824
Jonathan L. Wright
Principal Investigator
West Virginia University Healthcare
Morgantown West Virginia, 26506, United States More Info
Site Public Contact
Contact
304-293-7374
[email protected]
Adam M. Luchey
Principal Investigator
University of Wisconsin Carbone Cancer Center
Madison Wisconsin, 53792, United States More Info
Site Public Contact
Contact
800-622-8922
Kyle A. Richards
Principal Investigator
Medical College of Wisconsin
Milwaukee Wisconsin, 53226, United States More Info
Site Public Contact
Contact
414-805-3666
Scott Johnson
Principal Investigator
Cheyenne Regional Medical Center-West
Cheyenne Wyoming, 82001, United States More Info
Site Public Contact
Contact
303-777-2663
[email protected]
Nicholas DiBella
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Bladder Cancer

Phase:

Phase 3

Estimated Enrollment:

870

Study ID:

NCT05538663

Recruitment Status:

Recruiting

Sponsor:


ECOG-ACRIN Cancer Research Group

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.